Patrick Lu (Sirnaomics)

Short­ly af­ter its lat­est mega-round, Sir­naomics CEO Patrick Lu says it's time to go pub­lic

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter briefly putting off an IPO to pull in a $105 mil­lion Se­ries E round ear­li­er this month, Sir­naomics has filed for a Hong Kong pub­lic de­but.

CEO Patrick Lu is plan­ning on us­ing about half the pro­ceeds to de­vel­op and (if all goes well) com­mer­cial­ize one of the com­pa­ny’s lead small in­ter­fer­ing RNA (siR­NA) can­di­dates, STP705. Back in De­cem­ber, Sir­naomics said the can­di­date helped clear tu­mor cells in pa­tients with squa­mous cell skin can­cer in a Phase IIa tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.